- Home
- TOVX vs KLTOW Comparison
TOVX vs KLTOW Comparison
Compare TOVX & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOVX
- KLTOW
- Stock Information
- Founded
- TOVX 2001
- KLTOW N/A
- Country
- TOVX United States
- KLTOW United States
- Employees
- TOVX N/A
- KLTOW 3
- Industry
- TOVX Biotechnology: Pharmaceutical Preparations
- KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TOVX Health Care
- KLTOW Health Care
- Exchange
- TOVX Nasdaq
- KLTOW Nasdaq
- Market Cap
- TOVX 3.8M
- KLTOW N/A
- IPO Year
- TOVX 2006
- KLTOW 2022
- Fundamental
- Price
- TOVX $0.48
- KLTOW $0.26
- Analyst Decision
- TOVX Hold
- KLTOW
- Analyst Count
- TOVX 1
- KLTOW 0
- Target Price
- TOVX N/A
- KLTOW N/A
- AVG Volume (30 Days)
- TOVX 172.2K
- KLTOW N/A
- Earning Date
- TOVX 08-12-2025
- KLTOW N/A
- Dividend Yield
- TOVX N/A
- KLTOW N/A
- EPS Growth
- TOVX N/A
- KLTOW N/A
- EPS
- TOVX N/A
- KLTOW N/A
- Revenue
- TOVX N/A
- KLTOW N/A
- Revenue This Year
- TOVX N/A
- KLTOW N/A
- Revenue Next Year
- TOVX N/A
- KLTOW N/A
- P/E Ratio
- TOVX N/A
- KLTOW N/A
- Revenue Growth
- TOVX N/A
- KLTOW N/A
- 52 Week Low
- TOVX $0.40
- KLTOW N/A
- 52 Week High
- TOVX $7.37
- KLTOW N/A
- Technical
- Relative Strength Index (RSI)
- TOVX 49.42
- KLTOW N/A
- Support Level
- TOVX $0.42
- KLTOW N/A
- Resistance Level
- TOVX $0.48
- KLTOW N/A
- Average True Range (ATR)
- TOVX 0.03
- KLTOW 0.00
- MACD
- TOVX 0.02
- KLTOW 0.00
- Stochastic Oscillator
- TOVX 78.22
- KLTOW 0.00
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About KLTOW Klotho Neurosciences Inc. Warrant
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.